Hvilken er prisen på Radiopharm Theranostics Limited (RAD)

Prisen på Radiopharm Theranostics Limited (RAD) er $0.00846342

Hva er markedsverdien på Radiopharm Theranostics Limited (RAD)

Markedsverdien på Radiopharm Theranostics Limited (RAD) er $20.02M

Radiopharm Theranostics Limited (RAD) P/S-forhold

Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.

År	P/S-forhold	Endre
Ikke nok data for de angitte datoene.

År

P/S-forhold

Endre

Ikke nok data for de angitte datoene.

Selskap	P/S-forhold	Forskjell i P/S-forhold	Land
Vertex Pharmaceuticals Incorporated VRTX.US	10.17	-	US
Argenx SE ARGX.US	10.13	-	NL
CSL Limited CSL.AX	2.95	-	AU
Lonza Group AG LONN.SW	-	-	CH
UCB S.A. UCB.BR	4.74	-	BE

Selskap

P/S-forhold

Forskjell i P/S-forhold

Land